Ron Mazumder is a seasoned venture capital professional with a robust background in drug discovery and development, particularly within the realms of biomarkers and companion diagnostics. As a Partner at Illumina Ventures, he leverages over 30 years of R&D experience to identify and nurture innovative...
Ron Mazumder is a seasoned venture capital professional with a robust background in drug discovery and development, particularly within the realms of biomarkers and companion diagnostics. As a Partner at Illumina Ventures, he leverages over 30 years of R&D experience to identify and nurture innovative companies at the intersection of genomics and precision medicine. His expertise spans clinical development, including trial design and endpoints, personalized medicine, and immuno-oncology, making him a valuable asset in the rapidly evolving landscape of therapeutics and diagnostics.
At Illumina Ventures, Ron plays a pivotal role in shaping investment strategies that focus on transformative technologies in therapeutics, life science tools, and diagnostics. His current projects include serving on the Board of Directors for Actym Therapeutics, an engineered cell therapy company that is pioneering novel approaches to cancer treatment. Additionally, he acts as a Board Observer for Attovia Therapeutics, which is dedicated to advancing therapies for immune-mediated diseases. His involvement with these companies underscores his commitment to fostering innovation in targeted therapies, liquid biopsy, and pharmacodynamic biomarkers.
Ron’s extensive skill set includes biomarker discovery, immunoprofiling, and molecular profiling, which he applies to reverse translation and digital pathology initiatives. His ability to navigate complex clinical landscapes and his strategic insight into the commercialization of cutting-edge technologies position him as a thought leader in the venture capital community. Through his work, Ron is not only advancing the field of precision medicine but also contributing to the development of next-generation diagnostics that promise to revolutionize patient care.
